Effexor Will Rebound After “Cloud” Over Antidepressant Class Lifts, Wyeth Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Antidepressant growth has stalled amid publicity surrounding pediatric safety data, Wyeth acknowledges. Company still expects Effexor to top $3 bil. this year, helped by strong international sales.
You may also be interested in...
Off-Label Promotion, Class Labeling Debated During Antidepressant Hearing
The congressional investigation into antidepressants could renew interest in how off-label promotion is regulated in the U.S
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.